Search filters
 Trial Filters
Clear All

Phase

  • 1
  • 3
  • 1
  • 5
  • 5
  • 5

Lung Cancer Clinical Trials

A listing of Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 5 clinical trials
SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)

Primary Objectives: Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. Part 2: To assess the antitumor activity of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. Secondary Objectives: To assess the …

Phase 2
Learn more
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

Primary Objectives: Study is designed with two primary endpoints that will be analyzed on randomized participants at the time of the cutoff date for each given analysis (progression free survival [PFS] and overall survival [OS]). Study success is defined either on PFS or OS The primary objective is to determine …

Phase 3
Learn more
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma

Primary Objective: To determine the antitumor activity of SAR444245 in combination with other anticancer therapies. Secondary Objectives: To confirm the dose and to assess the safety profile of SAR444245 when combined with other anticancer therapies. To assess other indicators of antitumor activity. To assess the pharmacokinetic (PK) profile of SAR444245 …

Phase 2
Learn more
Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05)

Primary Objective: •To assess the tolerability and to determine the recommended doses of tusamitamab ravtansine in combination with pembrolizumab and tusamitamab ravtansine in combination with pembrolizumab and platinum-based chemotherapy with or without pemetrexed in the NSQ NSCLC population Secondary Objectives: To assess the safety and tolerability of tusamitamab ravtansine in …

Phase 2
Learn more
Safety and Efficacy Study of SAR442720 in Combination With Pembrolizumab in Advanced Malignancies

Primary Objective: Part 1: To characterize the safety and tolerability of SAR442720 in combination with pembrolizumab in patients with advanced solid tumors including NSCLC who progressed on anti-PD-1/PD L1 containing therapy and advanced colorectal cancer (CRC) after progression to all standard of care (SOC) therapy. To define the MTD and …

Phase 1
Learn more